303 related articles for article (PubMed ID: 30557039)
1. Overcoming the emerging drug resistance of smoothened: an overview of small-molecule SMO antagonists with antiresistance activity.
Zhang H; Sun Z; Liu Z; Song C
Future Med Chem; 2018 Dec; 10(24):2855-2875. PubMed ID: 30557039
[TBL] [Abstract][Full Text] [Related]
2. Molecular basis of drug resistance in smoothened receptor: An in silico study of protein resistivity and specificity.
Sinha N; Chowdhury S; Sarkar RR
Proteins; 2020 Mar; 88(3):514-526. PubMed ID: 31589795
[TBL] [Abstract][Full Text] [Related]
3. Current trends in Hedgehog signaling pathway inhibition by small molecules.
Ghirga F; Mori M; Infante P
Bioorg Med Chem Lett; 2018 Oct; 28(19):3131-3140. PubMed ID: 30177379
[TBL] [Abstract][Full Text] [Related]
4. Structural optimization on a virtual screening hit of smoothened receptor.
Song S; Jiang J; Zhao L; Wang Q; Lu W; Zheng C; Zhang J; Ma H; Tian S; Zheng J; Luo L; Li Y; Yang ZJ; Zhang X
Eur J Med Chem; 2019 Jun; 172():1-15. PubMed ID: 30939349
[TBL] [Abstract][Full Text] [Related]
5. Inhibition of Hedgehog-dependent tumors and cancer stem cells by a newly identified naturally occurring chemotype.
Infante P; Alfonsi R; Ingallina C; Quaglio D; Ghirga F; D'Acquarica I; Bernardi F; Di Magno L; Canettieri G; Screpanti I; Gulino A; Botta B; Mori M; Di Marcotullio L
Cell Death Dis; 2016 Sep; 7(9):e2376. PubMed ID: 27899820
[TBL] [Abstract][Full Text] [Related]
6. Discovery of [1,2,4]triazolo[4,3-a]pyridines as potent Smoothened inhibitors targeting the Hedgehog pathway with improved antitumor activity in vivo.
Tian N; Wu H; Zhang H; Yang D; Lv L; Yang Z; Zhang T; Quan D; Zhou L; Xie Y; Xu Y; Wei N; Zhang J; Chen M; Schmitz JC; Tian Y; Wu S
Bioorg Med Chem; 2020 Aug; 28(16):115584. PubMed ID: 32690258
[TBL] [Abstract][Full Text] [Related]
7. State of the art of Smo antagonists for cancer therapy: advances in the target receptor and new ligand structures.
Espinosa-Bustos C; Mella J; Soto-Delgado J; Salas CO
Future Med Chem; 2019 Mar; 11(6):617-638. PubMed ID: 30912670
[TBL] [Abstract][Full Text] [Related]
8. MRT-92 inhibits Hedgehog signaling by blocking overlapping binding sites in the transmembrane domain of the Smoothened receptor.
Hoch L; Faure H; Roudaut H; Schoenfelder A; Mann A; Girard N; Bihannic L; Ayrault O; Petricci E; Taddei M; Rognan D; Ruat M
FASEB J; 2015 May; 29(5):1817-29. PubMed ID: 25636740
[TBL] [Abstract][Full Text] [Related]
9. Small Molecule Inhibitors of the Hedgehog Pathway in the Treatment of Basal Cell Carcinoma of the Skin.
Danhof R; Lewis K; Brown M
Am J Clin Dermatol; 2018 Apr; 19(2):195-207. PubMed ID: 28887802
[TBL] [Abstract][Full Text] [Related]
10. Discovery of Hedgehog Antagonists for Cancer Therapy.
Khatra H; Bose C; Sinha S
Curr Med Chem; 2017; 24(19):2033-2058. PubMed ID: 28302010
[TBL] [Abstract][Full Text] [Related]
11. Design, Synthesis, and Structure-Activity Relationship of Tetrahydropyrido[4,3-d]pyrimidine Derivatives as Potent Smoothened Antagonists with in Vivo Activity.
Lu W; Liu Y; Ma H; Zheng J; Tian S; Sun Z; Luo L; Li J; Zhang H; Yang ZJ; Zhang X
ACS Chem Neurosci; 2017 Sep; 8(9):1980-1994. PubMed ID: 28618224
[TBL] [Abstract][Full Text] [Related]
12. Design and biological evaluation of phenyl imidazole analogs as hedgehog signaling pathway inhibitors.
Sun C; Zhang Y; Wang H; Yin Z; Wu L; Huang Y; Zhang W; Wang Y; Hu Q
Chem Biol Drug Des; 2021 Mar; 97(3):546-552. PubMed ID: 32946174
[TBL] [Abstract][Full Text] [Related]
13. Hedgehog pathway and smoothened inhibitors in cancer therapies.
Chahal KK; Parle M; Abagyan R
Anticancer Drugs; 2018 Jun; 29(5):387-401. PubMed ID: 29537987
[TBL] [Abstract][Full Text] [Related]
14. Novel-smoothened inhibitors for therapeutic targeting of naïve and drug-resistant hedgehog pathway-driven cancers.
Li QR; Zhao H; Zhang XS; Lang H; Yu K
Acta Pharmacol Sin; 2019 Feb; 40(2):257-267. PubMed ID: 29777201
[TBL] [Abstract][Full Text] [Related]
15. DYRK1B as therapeutic target in Hedgehog/GLI-dependent cancer cells with Smoothened inhibitor resistance.
Gruber W; Hutzinger M; Elmer DP; Parigger T; Sternberg C; Cegielkowski L; Zaja M; Leban J; Michel S; Hamm S; Vitt D; Aberger F
Oncotarget; 2016 Feb; 7(6):7134-48. PubMed ID: 26784250
[TBL] [Abstract][Full Text] [Related]
16. Hedgehog Signaling: From Basic Biology to Cancer Therapy.
Wu F; Zhang Y; Sun B; McMahon AP; Wang Y
Cell Chem Biol; 2017 Mar; 24(3):252-280. PubMed ID: 28286127
[TBL] [Abstract][Full Text] [Related]
17. ABT-199 inhibits Hedgehog pathway by acting as a competitive inhibitor of oxysterol, rather as a BH3 mimetic.
Wang J; Zhang Y; Huang WJ; Yang J; Tang WG; Huang TM; Tan WF
Acta Pharmacol Sin; 2021 Jun; 42(6):1005-1013. PubMed ID: 32855528
[TBL] [Abstract][Full Text] [Related]
18. Overcoming the resistance mechanisms of Smoothened inhibitors.
Dong X; Wang C; Chen Z; Zhao W
Drug Discov Today; 2018 Mar; 23(3):704-710. PubMed ID: 29326074
[TBL] [Abstract][Full Text] [Related]
19. A computational study of hedgehog signalling involved in basal cell carcinoma reveals the potential and limitation of combination therapy.
Buetti-Dinh A; Jensen R; Friedman R
BMC Cancer; 2018 May; 18(1):569. PubMed ID: 29776351
[TBL] [Abstract][Full Text] [Related]
20. Biochemical characterization of smoothened receptor antagonists by binding kinetics against drug-resistant mutant.
Shimizu Y; Ishii T; Ogawa K; Sasaki S; Matsui H; Nakayama M
Eur J Pharmacol; 2015 Oct; 764():220-227. PubMed ID: 26048307
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
